Trials / Withdrawn
WithdrawnNCT05927610
Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma
Evaluating the Role of Cerebrospinal Fluid (CSF) Cell-free DNA (cfDNA) as a Prognostic Biomarker in Glioblastoma
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to determine the utility of cerebrospinal fluid (CSF) cell-free DNA (cfDNA) as a prognostic biomarker in glioblastoma (GBM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Lumber Puncture | During the lumbar puncture/LP, 20cc will be collected per standard practice in adult patients. LP will be performed either at bedside or under interventional radiology (IR) guidance (due to patient anatomy). |
Timeline
- Start date
- 2023-06-19
- Primary completion
- 2024-02-15
- Completion
- 2024-02-15
- First posted
- 2023-07-03
- Last updated
- 2025-05-21
Source: ClinicalTrials.gov record NCT05927610. Inclusion in this directory is not an endorsement.